SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL), a fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited (BOM: 530549, NSE: SHILPAMED), announced a strategic licensing agreement to commercialize a biosimilar across Latin America. The partnership combines SBPL’s biologics development and manufacturing expertise with SteinCares’ integrated regional commercial platform.
Latin America Market Access: SteinCares’ established regional infrastructure provides SBPL with immediate market entry across diverse regulatory environments (Brazil, Mexico, Argentina, Colombia, etc.) without building proprietary commercial teams.
Manufacturing Cost Advantage: SBPL’s Indian manufacturing base offers cost‑competitive biosimilar production, critical for price‑sensitive Latin American healthcare systems and government procurement.
Risk Sharing: The development‑manufacturing / commercialization split aligns incentives—SBPL ensures product quality and supply; SteinCares drives market penetration and revenue generation.
Biosimilar Growth Trend: Latin America represents an emerging biosimilar market with increasing regulatory harmonization and payer acceptance; early partnerships secure first‑mover positioning.
Market Context
Factor
Impact
Latin America Biosimilar Market
Projected double‑digit growth driven by healthcare cost containment and patent expiries of major biologics
SteinCares Positioning
Leading specialty pharma platform with established relationships across hospitals, pharmacies, and government channels
Shilpa Medicare Expansion
Biosimilar partnership extends SBPL’s global footprint beyond India and established markets into high‑growth Latin America
Forward‑Looking Statements This brief contains forward‑looking statements regarding product registration timelines, commercial launch dates, and market penetration expectations. Actual results may differ due to risks including regulatory approval delays, competitive biosimilar launches, and pricing pressure in Latin American markets.-Fineline Info & Tech
By Fineline Cube